Roivant Sciences (NASDAQ:ROIV – Get Free Report) is anticipated to announce its earnings results before the market opens on Monday, February 10th. Analysts expect the company to announce earnings of ...

BofA lowered the firm’s price target on Roivant Sciences (ROIV) to $12 from $13 and keeps a Neutral rating on the shares. The fiscal Q3 call ...

In a report released yesterday, Chi Meng Fong from Bank of America Securities reiterated a Hold rating on Roivant Sciences (ROIV – Research ...

Roivant Sciences operates as a biopharmaceutical company, developing novel therapies for diseases with significant unmet needs. The company's distinct business model involves creating "Vants," or ...

Roivant Sciences posted earnings that exceeded expectations, with substantial progress in its diversified drug pipeline.

Roivant Sciences ROIV reported its Q3 earnings results on Monday, February 10, 2025 at 07:00 AM. Here's what investors need ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Ladies and gentlemen, thank you for standing by. Welcome to Roivant Second Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. After the speaker's presentation ...

Roivant Sciences showcased an active quarter marked by significant pipeline developments, including a new cutaneous sarcoidosis trial for brepocitinib and upcoming MG and CIDP data for its anti ...